NBP is the ticker symbol for NovaBridge Biosciences, a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks NBP with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is NBP a good stock to buy?

NBP is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/NBP.

Where does 13F Pro source NBP data?

All NovaBridge Biosciences fundamentals and ownership data come directly from SEC EDGAR. NovaBridge Biosciences files with the SEC under CIK 1778016. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

NovaBridge Biosciences(NBP)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

NovaBridge Biosciences (NBP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. NBP is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q4 2025), NovaBridge Biosciences reports net income of $-30.8M, free cash flow of $-14.6M. Top institutional holders of NBP by reported 13-F value include Hillhouse Capital Advisors, Ltd., MORGAN STANLEY, AIHC Capital Management Ltd, based on the most recent SEC filings. NBP trades on the Nasdaq exchange and files with the SEC under CIK 1778016. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NBP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NovaBridge Biosciences directly from SEC EDGAR.

Net Income

$-30.8M

Free Cash Flow

$-14.6M

NBP key financials by period

NovaBridge Biosciences reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2023	20-F	$632.0K	$-207.7M	—
FY 2022	20-F	$-1.6M	$-371.1M	—
FY 2021	20-F	$88.0M	$-2.3B	—
FY 2020	20-F	$1.5B	$470.9M	31.3%
FY 2019	20-F	$30.0M	$-1.5B	—
FY 2018	20-F	$53.8M	$-402.8M	—

Institutions holding NBP

Institutional investors reporting a position in NovaBridge Biosciences on SEC Form 13F.
Institution	Shares	Value	Reported
Hillhouse Capital Advisors, Ltd.	5,980,568	$11.7M	2026-06-30
MORGAN STANLEY	3,653,228	$7.1M	2026-06-30
AIHC Capital Management Ltd	2,878,033	$5.6M	2026-06-30
Siren, L.L.C.	2,004,739	$3.9M	2026-06-30
MARSHALL WACE, LLP	1,231,946	$2.4M	2026-06-30
Candriam S.C.A.	1,132,563	$2.2M	2026-06-30
ADAGE CAPITAL PARTNERS GP, L.L.C.	1,000,000	$1.9M	2026-06-30
TWO SIGMA INVESTMENTS	851,348	$1.7M	2026-06-30
RENAISSANCE TECHNOLOGIES	758,226	$1.5M	2026-06-30
BlackRock	686,208	$1.3M	2026-06-30

SEC EDGAR: CIK 1778016 →

NovaBridge Biosciences

NBP

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.